Gesynta Pharma AB announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's drug candidate GS-248 for the treatment of systemic sclerosis. GS-248 is currently being evaluated in a Phase II clinical trial as a treatment for Raynaud’s phenomenon secondary to systemic sclerosis.
- Read more about Systemic sclerosis drug of Gesynta Pharma gets Orphan Drug Designation by USFDA
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/systemic-sclerosis-drug-of-gesynta-pharma-gets-orphan-drug-designation-by-usfda
No comments:
Post a Comment